December 09, 2025 a 08:38 am
MDT: Analysts Ratings - Medtronic plc
Medtronic plc maintains its stature in the medical device industry with consistent innovations across its diverse segment portfolio. As the market continues to navigate economic uncertainties, Medtronic remains a point of interest among investors, evidenced by steady recommendations favoring Holds and Buys. The company's financial health and market position suggest potential stability, yet challenges could arise from fluctuating market demands and regulatory landscapes.
Historical Stock Grades
The recent analyst data for Medtronic showing on December 1, 2025, indicates a consistent sentiment with the most "Hold" recommendations, followed by "Buy" endorsements.
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 12 | |
| Hold | 16 | |
| Sell | 0 | |
| Strong Sell | 0 |
Image: Historical trends in analyst recommendations for Medtronic plc.
Image: Stock performance of Medtronic plc over the recent months.
Sentiment Development
- Over recent months, the number of "Hold" ratings has steadily increased, reaching a peak in December 2025.
- The "Buy" ratings have remained stable, indicating moderate positive sentiment.
- Ratings for "Strong Sell" and "Sell" have been largely absent, suggesting low bearish sentiment.
- The stability of "Strong Buy" ratings reflects cautious optimism about Medtronic’s long-term prospects.
Percentage Trends
There has been a notable shift towards more conservative "Hold" ratings, potentially indicating market apprehension. The balance of recommendations reflects strategic caution among analysts:
- December 2025: 16% Strong Buy, 48% Buy, 64% Hold.
- The reduction in "Strong Buy" from earlier months indicates growing market caution.
- The steady percentage of "Buy" recommendations hints at persistent confidence in fundamental value.
- Overall, there's a trend toward neutrality and caution among analysts as growth outlook stabilizes.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-11-20 | Overweight | Overweight | Barclays |
| 2025-11-20 | Hold | Hold | Truist Securities |
| 2025-11-19 | Neutral | Sell | Goldman Sachs |
| 2025-11-19 | Overweight | Overweight | Morgan Stanley |
| 2025-11-19 | Outperform | Outperform | RBC Capital |
Analyst Recommendations with Change of Opinion
Recent changes in opinions suggest a cautious reevaluation of Medtronic's market position, with some upgrades reflecting revised confidence:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-11-19 | Neutral | Sell | Goldman Sachs |
| 2025-06-30 | Peer Perform | Underperform | Wolfe Research |
| 2025-03-04 | Buy | Neutral | Citigroup |
| 2024-10-10 | Outperform | Sector Perform | RBC Capital |
| 2024-08-15 | Neutral | Sell | UBS |
Interpretation
The analysis indicates that Medtronic plc is seen as a stable entity with moderate growth potential amidst a fluctuating market environment. Analysts' steady inclination towards "Hold" and "Buy" ratings reflects confidence in its operational consistency, despite external pressures. However, the moderate downgrade in "Strong Buy" suggests a cautious outlook. Changes in recommendations, such as upgrades from "Sell" to "Neutral," point to renewed confidence, possibly driven by strategic initiatives or market conditions. Overall, while there might be emerging uncertainties, the underlying sentiment remains cautiously optimistic.
Conclusion
Medtronic plc's standing in the medical technology market presents a blend of risks and opportunities. While its diverse portfolio underpins fundamental strength, external market dynamics pose challenges. Analysts have shown a trend toward conservative optimism, with most opting for "Hold" positions, indicating belief in stability rather than aggressive growth. Shifts in sentiment suggest that while trust in Medtronic's resilience exists, the cautious market approach reflects broader economic concerns. Consequently, Medtronic stands as a potentially low-risk investment, appealing to those favoring long-term stability over short-term gains.